Drug Profile
Interferon alpha 2 gene therapy - Genenta Science
Alternative Names: Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 - Genenta Science; Genetically modified HSPCs - Genenta Science; Temferon; Temferon_GBM; Temferon_MMLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Genenta Science
- Developer AGC Biologics; Genenta Science
- Class Antineoplastics; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Multiple myeloma
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a phase I/IIa TEM-GBM trial in Glioblastoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 20 Oct 2023 Efficacy data from a phase I/II TEM-GBM trial in Glioblastoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Sep 2023 Pharmacodynamics and efficacy data from a phase I/II TEM-GBM trial in Glioblastoma presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)